GlassScriptPhysician profile
Anna Doolittle Eisenberg-Spence
NPI 1366637514
$3,918.94
in general payments reported to CMS, 2019-2025
22 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,854 · 2022: $1,135 · 2023: $272 · 2024: $537 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $679 · Long Term Medical Supply Or Device Loan: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.25 |
| Long Term Medical Supply Or Device Loan | $249.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,834.42 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $382.41 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $177.23 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $153.81 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.63 | 2024 | Xifaxan |
| Ardelyx, INC. | $125.00 | 2024 | Ibsrela |
| Celltrion USA INC. | $125.00 | 2024 | Zymfentra |
| Abbvie INC. | $122.62 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.91 | 2024 | Entyvio |
| Novo Nordisk INC | $119.40 | 2025 | Wegovy |
| Pfizer INC. | $112.28 | 2021-2022 | |
| Daiichi Sankyo INC. | $95.90 | 2021-2022 | |
| Gilead Sciences, INC. | $80.51 | 2021-2022 | |
| Amgen INC. | $60.99 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.03 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $46.18 | 2021 | |
| Puma Biotechnology, INC. | $38.19 | 2021 | |
| Janssen Biotech, INC. | $33.74 | 2021 | |
| Seagen INC. | $25.00 | 2022 | |
| Genentech USA, INC. | $24.38 | 2022 | |
| Intercept Pharmaceuticals, INC. | $22.47 | 2023 | Ocaliva |
| Qol Medical, LLC | $19.84 | 2024 | Sucraid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Eisenberg-Spence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.